These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19822271)

  • 1. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.
    Moet GJ; Watters AA; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):319-22. PubMed ID: 19822271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.
    Jones RN; Fritsche TR; Moet GJ
    Diagn Microbiol Infect Dis; 2008 May; 61(1):76-9. PubMed ID: 18221852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.
    Jones RN; Sader HS; Flamm RK; Watters AA
    Diagn Microbiol Infect Dis; 2013 May; 76(1):110-2. PubMed ID: 23490010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin).
    Thamlikitkul V; Tiengrim S; Chalermsri C; Sae-Jong R; Suddhichupaiboon S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S196-202. PubMed ID: 21721447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol.
    Tschudin-Sutter S; Frei R; Widmer AF
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):286-7. PubMed ID: 21353954
    [No Abstract]   [Full Text] [Related]  

  • 6. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels.
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2005 May; 52(1):67-9. PubMed ID: 15878446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample.
    Jones RN; Watters AA; Flamm RK; Sader HS
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):237-8. PubMed ID: 23434498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro evaluation of "piperacillin and tazobactum" combination in a tertiary-care hospital--a preliminary study.
    Kumari N; Mohapatra TM; Rai A; Bhattacharya SK
    Indian J Pathol Microbiol; 2006 Jan; 49(1):57-8. PubMed ID: 16625981
    [No Abstract]   [Full Text] [Related]  

  • 10. Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
    Thomson KS; Black J; Moland ES; Reuben J; Wiles T; Brasso W
    Int J Antimicrob Agents; 2008 Jan; 31(1):83-5. PubMed ID: 17996426
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
    WaKabongo M; Stucki ZN; Torbert DP; Olweny J
    J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671
    [No Abstract]   [Full Text] [Related]  

  • 12. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum.
    Singh N; Obman A; Husain S; Aspinall S; Mietzner S; Stout JE
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1989-92. PubMed ID: 15155189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Fujimura S; Takane H; Nakano Y; Watanabe A
    J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacological properties and clinical efficacies of tazobactam/piperacillin (Zosyn 2.25, Zosyn 4.5), an injectable antibiotic combined with beta-lactamase inhibitor].
    Uji T; Hashimoto Y
    Nihon Yakurigaku Zasshi; 2009 Jun; 133(6):351-8. PubMed ID: 19521033
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.
    Gagliotti C; Sarti M; Sabia C; Gargiulo R; Rossolini GM; Carillo C; Cassani C; Cipolloni AP; Pedna F; Rossi MR; Incerti SS; Testa G; Venturelli C; Moro ML
    New Microbiol; 2011 Jan; 34(1):97-9. PubMed ID: 21344153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
    Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
    Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.